Navigation Links
Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program
Date:10/14/2010

SEATTLE, Oct. 14 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER) today announced that the National Institute on Drug Abuse (NIDA) has provided an additional grant to fund clinical studies for the Company's Addiction program. This grant, which is for a total of approximately $3.6 million to be paid over a four-year period in equal amounts, will fund direct and indirect costs of Phase 2 clinical studies to be conducted by researchers at the New York State Psychiatric Institute (NYSPI). In Omeros' Addiction program, the Company is developing proprietary compositions that include peroxisome proliferator-activated receptor gamma (PPARgamma) agonists for the prevention and treatment of addiction to substances of abuse, such as opioids, nicotine and alcohol, as well as other compulsive behaviors, including eating disorders. Data from earlier European pilot clinical studies and animal models of addiction have demonstrated a previously unknown link between PPARgamma and addiction disorders.

Earlier this year, Omeros announced that NIDA agreed to fund substantially all of the costs of a Phase 2 clinical study to be conducted by NYSPI researchers to evaluate a PPARgamma agonist for the treatment of addiction to prescription opioids. The NIDA support announced today will be used to fund additional Phase 2 clinical studies to evaluate the effect of a PPARgamma agonist in combination with other agents on the use of heroin and cigarettes.  These clinical studies will also be conducted at the NYSPI and will be led by the recipients of this grant award, Dr. Sandra D. Comer and Dr. Adam Bisaga. Omeros will have the right to reference the data obtained from these studies for subsequent submissions to the FDA and will retain all other rights in connection with its Addiction program.

"This latest grant from NIDA underscores the potential of our Addiction program to yield a
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Omeros Secures $40 Million Committed Equity Financing Facility
2. Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
3. Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
4. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
5. Omeros Commences Initial Public Offering of Common Stock
6. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
7. Omeros Appoints New Vice President of Clinical Development
8. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
9. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
10. Omeros and BlueCrest Announce $20 Million Debt Facility
11. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent ... viruses is the Epstein Barr Virus (EBV), and one of ... a chronic inflammatory disease that destroys the body’s joints. As ... have high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of ... of tinnitus. Patients listen to sound therapy that is ... of weeks to months, their tinnitus volume decreases. , AudioNotch ... Music and Notched White Noise. Now, AudioNotch is pleased to ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... Texas , Jan. 14, 2014 The ... and research medicinal plants and therapeutic derivatives thereof ... health professionals, and researchers about the challenges of ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... Aug. 14 Pressure,BioSciences, Inc. (Nasdaq: PBIO ) ... the second quarter of 2008 was $120,184 compared to,$202,127 ... from the sale,of PCT products and services was $117,698 ... to $136,355 for the prior year period. During the,second ...
... drugs and devices that have ... the quality of human life -, PALO ALTO, Calif., ... announced that its chronic angina therapy,Ranexa(R) (ranolazine extended-releases tablets) has ... 2008 award which honors the,best pharmaceutical agent and best biotechnology ...
... TROY, Mich., Aug. 14 CJPS Enterprises, LLC, ... today that it,has put online more resources for ... market, or to grow their existing healthcare,business. Those ... This project is dedicated to providing users ...
Cached Biology Technology:Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 2Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 3Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 4Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 5Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 6Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 7Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 8Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update 9CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award 2CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award 3The Michigan Life Sciences Pipeline Adds More Resources On Its Website 2
(Date:4/18/2014)... NC Seeds that sprout as soon as they,re planted ... need to be more careful. In the wild, a plant ... day would risk disaster. More than just an insurance policy ... that seed dormancy has long-term advantages too: Plants whose ... rise to more species, finds in a team of researchers ...
(Date:4/17/2014)... , Respiratory syncytial virus (RSV) is a ... life-threating illness in very young and elderly populations. ... enters host cells through the fusion protein RSV ... interfering peptides that prevent bundle formation limit RSV ... susceptible to degradation. In this issue of the ...
(Date:4/17/2014)... Gauthier and Professor Luca Razzari of the nergie ... large grants from the John R. Evans Leaders ... for the acquisition of state-of-the-art biotech and nanophotonics ... grants from the Ministre de l,Enseignement suprieur, de ... Technologie (MESRST). These new laboratories will help us ...
Breaking Biology News(10 mins):Plants with dormant seeds give rise to more species 2JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... bio-based plastic packaging is not only eco-friendly but also ... The plastic packaging industry is moving towards completely bio-based ... the production of plastics equates to approximately five per ... per cent of all plastics are used in packaging, ...
... well-known fairy tale, Rumpelstiltskin used magic to weave straw into ... to turn straw (and other forms of biomass) into today,s ... in which minute particles of gold dot the surface of ... two materials are strong enough to breaks the O-O bond ...
... Software Inc. of Ottawa, Canada announced today it ... lead its company awareness and lead generation campaigns. ... in developing integrated marketing programs that target embedded ... messaging and positioning, PR, content development, partner co-marketing ...
Cached Biology News:Plastic packaging industry is moving towards completely bio-based products 2Gases from grasses 2Gases from grasses 3Crank Software Selects TREW Marketing for Embedded Industry Outreach 2Crank Software Selects TREW Marketing for Embedded Industry Outreach 3
...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... package that provides crystallographers with an ... creation, set-up of experimental conditions and ... software helps crystallographers through the most ... Design of Crystallization ...
BD Falcon insert HTS 96 well, square A-bottom with lid. PET membrane, sterile. (5/ca) Packaging: 5 / pack, 5 / case ...
Biology Products: